The Supreme Court on Friday granted the HIV-prevention field a historic win — yet with a major caveat — as it upheld a ...

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

The FDA approved Gilead's HIV prevention drug lenacapavir, ... The drug will be marketed under the name Yeztugo and sell for an annual price of $28,218, or $14,109 per injection.

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention ...